Literature DB >> 29899390

Correction: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.

Astrid Lièvre1,2,3, Bérèngere Ouine4, Jim Canet5, Aurélie Cartier4, Yael Amar5, Wulfran Cacheux6,7, Odette Mariani8, Rosine Guimbaud9,10, Janick Selves9,11, Thierry Lecomte12,13, Serge Guyetant14, Ivan Bieche7, Frédérique Berger5,15, Leanne de Koning16.   

Abstract

Supplementary Table 1 and the Supplementary Figure legends were not included when this manuscript was first published. The files are now available here.

Entities:  

Year:  2018        PMID： 29899390      PMCID： PMC6079395          DOI： 10.1038/s41416-018-0130-x

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


Correction to: Br J Cancer (2018) 117, 1819–1827; 10.1038/bjc.2017.353; published online 12 October 2017 Supplementary Table 1 and the Supplementary Figure Legends were not included when this manuscript was first published. The files are now available here. Supplementary Table 1 Supplementary Figure Legends
  1 in total

1.  Elevated FPR confers to radiochemoresistance and predicts clinical efficacy and outcome of metastatic colorectal cancer patients.

Authors:  Qing-Gen Chen; Lei Zhang; Fan Sun; Shu-Qi Li; Xia-Hong You; Yu-Huan Jiang; Wei-Ming Yang; Qiong-Hui Zhong; Xiao-Zhong Wang; Hou-Qun Ying
Journal:  Aging (Albany NY)       Date:  2019-03-21       Impact factor: 5.682
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.